Sep 17 |
Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus
|
Sep 16 |
Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus
|
Sep 14 |
Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024
|
Aug 30 |
Cullinan Therapeutics: Fundraising Capability, Emergence In Autoimmune Disease
|
Aug 28 |
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
|
Aug 24 |
We Think Cullinan Therapeutics (NASDAQ:CGEM) Can Afford To Drive Business Growth
|
Aug 8 |
Cullinan Therapeutics GAAP EPS of -$0.75
|
Aug 8 |
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
|
Jun 9 |
Checking Into Cullinan Therapeutics
|
Jun 4 |
Institutional owners may ignore Cullinan Therapeutics, Inc.'s (NASDAQ:CGEM) recent US$92m market cap decline as longer-term profits stay in the green
|